UnTIL We Meet Again: Testing TIL Therapies in an Ex Vivo Platform

Sep 30, 2021 11:00:00 AM / by Champions Oncology posted in Immuno-Oncology, Ex Vivo Platforms

Tumor infiltrating lymphocyte (TIL)-based immunotherapy is currently at the forefront of cutting-edge immuno-oncology treatments. TILs are a type of adoptive cellular therapy (ACT) using lymphocytes that are found within tumor tissues; most of these lymphocytes are T cells that can specifically target tumor cells. For TIL-based therapies, these T cells are harvested from a tumor biopsy, expanded ex vivo, and infused back into the patient. Advances in TIL-based therapies are driven by preclinical characterization and screening of TILs against a wide array of tumor types.

Read More →

Regulatory T Cells in CLL: Immune System Exhaustion and Potential Restoration, and the Role of Immuno-Oncology Therapies

Sep 2, 2021 1:00:00 PM / by Champions Oncology posted in Immuno-Oncology, Hematological Malignancies

Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring hematologic malignances with no known cure and is defined by the clonal expansion and accumulation of CD5+ B cells in the blood and bone marrow. Standard treatments to manage disease include chemotherapy and rituximab (anti-CD20 monoclonal antibody). Newer therapies that are less prone to resistance or treatment failure are currently being examined, such as Bruton tyrosine kinase (BTK) inhibitors and anti-CD20 biosimilars[1],[2].

Read More →

Immune Checkpoint Blockade Strategies in Renal Cell Carcinoma

Mar 18, 2021 1:45:00 PM / by Champions Oncology posted in Solid Tumor Oncology, Immuno-Oncology

 

Renal cell carcinoma (RCC) is a common cancer of the genitourinary tract that has very poor survival outcomes if metastatic. RCC is now understood to be composed of several different types of cancer with different genetic features and varied clinical responses. Histological diagnosis has been the primary method to diagnose RCC and has been used to define three major RCC subtypes, including the most common subtype, clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (PRCC; further divided into two subtypes), and chromophobe renal cell carcinoma (ChRCC)[1]. More recent comparative genomic and phenotypic analysis has identified mutations and epigenetic modifications associated with different histological subtypes[2]. Across all subtypes, increased DNA hypermethylation and gene alterations in CDKN2A were associated with a poor prognosis as was an increased Th2 immune gene signature. For ccRCC, increased levels of mRNA transcripts associated with ribose metabolism and the immune response were associated with poor survival. ccRCC is also defined by the early loss of chromosome 3p, which in turn causes a loss of heterozygosity for the VHL, PBRM1, SETD2, and BAP1 tumor suppressor genes and subsequent mutation of these genes that leads to tumorigenesis[3]. There is also a subset of ChRCC with a unique metabolic expression pattern that is associated with extremely poor survival2. PRCC can be classified as type 1, for which PBRM1 mutations are linked to poor survival but type 2 PRCC has increased expression of glycolysis and metabolism related mRNA transcripts2.

 

Read More →

UnTIL We Meet Again -- Testing TIL Therapies in an Ex Vivo Platform

Nov 5, 2020 11:00:00 AM / by Champions Oncology posted in Immuno-Oncology, Ex Vivo Platforms

Read More →

Immune Checkpoint Inhibitors and Clinical Flow Cytometry

May 13, 2020 11:15:07 AM / by Champions Oncology posted in Immuno-Oncology

Caner Cells

The field of oncology has been transformed by the approval and implementation of immune checkpoint inhibitors. Cancer cells can tamper with a variety of self-defense mechanisms, including upregulating expression of immune checkpoint molecules on cytotoxic T cells and natural killer (NK) cells, such as PD-1 and CTLA-4. Overexpression of these markers is associated with T cell exhaustion and allows for tumor cells to evade detection. Immune checkpoint inhibitors target these molecules, which restores immune surveillance and anti-tumor responses by T cells.

Read More →
Content not found